This commentary in Clinical and Translational Science by Drs. Craig R. Rayner, Patrick F. Smith, Kevin Hershberger, and David Wesche shares insights from past experiences with H5N1 and pH1N1 outbreaks and how we can apply them to optimize development of COVID‐19 candidate therapeutics. With a particular focus on influenz, it discusses anti‐infective posology in settings where quality and timely availability of data is challenging. It also emphasizes the need for multi-sectoral collaboration and coordination. Full pdf is accessible on ascpt.com.